Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

I-tech

57.40 SEK

Less than 1K followers

ITECH

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+0.70 %
-20.94 %
-35.94 %
-44.00 %
-1.03 %
+15.26 %
+1.06 %
-14.33 %
+132.72 %

I-tech operates in marine technology. The company conducts research and development of substances that inhibit marine fouling on ship hulls. In addition, the products can be used for various marine installations in fish farming and offshore. Customers are found in the marine paint industry and among other players in the shipping industry. I-Tech was founded in 2000 and has its headquarters in Mölndal.

Read more
Market cap
688.67M SEK
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.2.
2026

Annual report '25

7.5.
2026

Interim report Q1'26

21.8.
2026

Interim report Q2'26

All
Press releases
3rd party
ShowingAll content types
Third party research11/27/2025, 9:39 AM

I-tech: Proposed non-renewal of Selektope in the EU - ABG

* European Commission drafts proposal for non-renewal of Selektope* Limited impact on near-term estimates, EU ~2% of total sales* Voting expected to occur some time in H1'26, final decision in mid-26European Commission drafts proposal for non-renewal...

I-tech
Regulatory press release11/27/2025, 7:45 AM

I-Tech strongly rejects the European Commission’s proposed non-renewal of Medetomidine under the EU Biocidal Products Regulation (BPR)

I-tech
Press release11/24/2025, 9:00 AM

I-Tech and Havey sign MoU to collaborate on the development of next-generation antifouling materials

I-tech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release11/18/2025, 9:00 AM

I-Tech's Nomination Committee appointed

I-tech
Press release10/21/2025, 8:25 AM

Redeye: I-Tech (Q3 Review) - Forecasts Trimmed, Long-Term View Unchanged

I-tech
Third party research10/20/2025, 7:17 AM

I-tech: Customer slowdown tempers growth - ABG

* Q3 softer due to sizeable customer trimming '25 volumes* '25e-'27e sales cut by 11-6% and '26e-'27e EBIT by 12-8%* We believe I-Tech remains strongly positioned to grow market shareGrowth dampened by customer volume cutsI-Tech reported weaker than ...

I-tech
Third party research10/17/2025, 7:05 AM

I-tech: Q3 impacted by weaker market conditions - ABG

Sales -18% vs. ABGSCe, EBIT SEK 11m vs. ABGSCe 16m* Newbuild market down 50% y-o-y, affecting growth* Sizeable customer has reduced planned volumes for '25Q3 resultsQ3 sales came in lower than expected at SEK 41m (-18% vs. ABGSCe 50m). The company writes...

I-tech
Regulatory press release10/17/2025, 6:00 AM

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the third quarter 2025

I-tech
Third party research10/7/2025, 7:09 AM

I-tech: Sales recovery expected in Q3 - ABG

* Report out on 17 October* Q3e sales of SEK 50m, +23% y-o-y, EBIT SEK 16m (9m)* Q3 rebound expected after Q2 dip Q3 expectations We estimate Q3 sales of SEK 50m, +23% y-o-y (+35% organic, -12% FX). We expect Q3 to demonstrate that Q2 was a temporary...

I-tech
Press release8/25/2025, 9:24 AM

Redeye: I-Tech - Q2 Review – Temporary Slowdown

I-tech
Third party research8/25/2025, 5:28 AM

I-tech: A pause, not a stop - ABG

* Weaker Q2 due to natural quarterly variations* Cut '25e-'27e EBIT by 12-13%* Demand intact, rebound expected in Q3Growth halted, but we expect a rebound in Q3I-Tech reported weaker Q2 sales of SEK 32m (-39% vs. ABGSCe, -26% y-o-y) and EBIT of SEK 5m...

I-tech
Third party research8/22/2025, 7:42 AM

I-tech: Big Q2 miss halts sales growth - ABG

* Sales -39% vs. ABGSCe, EBIT SEK 5m vs. ABGSCe 16m * Weak Q2 due to inventory build-up following strong Q4/Q1* Gross margin continues to improve (59% vs. ABGSCe 56%) Weaker Q2 than expected Sales came in lower than expected at SEK 32m (-39% vs. ABGSCe...

I-tech
Regulatory press release8/22/2025, 6:00 AM

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the second quarter 2025

I-tech
Third party research8/11/2025, 7:08 AM

I-Tech: Resilient growth ahead despite FX headwinds - ABG

Q2e sales of SEK 52m, 22% y-o-y, adj. EBIT of SEK 17m (12m) FX headwinds, but we expect customer growth to remain solid Minor estimate changes ahead of report Q2 expectations We anticipate a negative FX impact in Q2 from the depreciation of the USD/SEK...

I-tech
Regulatory press release6/13/2025, 1:30 PM

I-Tech announces outcome of warrant exercise

I-tech
Third party research5/23/2025, 12:27 PM

I-tech: Announce one year extension of Selektope approval - ABG

Q1 revenues 3% below, EBIT DKK -1m vs. ABGSCe DKK 11m FY'25 guidance maintained, as expected Consensus to lower '25e EBITDA by ~10% on Q1 miss Q1 revenues 3% below, EBIT DKK -1m vs. ABGSCe DKK 11m North Media's Q1 revenues of DKK 311m came in 3% below...

I-tech
Press release5/23/2025, 11:40 AM

I-Tech announces a one year extension of the current EU Approval for Selektope (Medetomidine)

I-tech
Regulatory press release5/15/2025, 3:30 PM

Report from the Annual General Meeting 2025 of I-tech AB (publ)

I-tech
Press release5/12/2025, 8:23 AM

Redeye: I-Tech Q1 Review - Upward Adjustments

I-tech
Third party research5/9/2025, 5:25 AM

I-tech: The winning formula continues to unfold - ABG

Strong Q1 sales of SEK 57m, +49% y-o-y '25e-'27e sales and EBIT up 5-6% and 9%, respectively Growth in market share should overshadow market uncertainty The growth journey continues I-Tech reported strong sales of SEK 57m (+9% vs. ABGSCe, +49% y-o-y)...

I-tech
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.